# Congressional stock trades in CRSP (CRISPR Therapeutics AG)

Congressional stock trades in CRISPR Therapeutics AG (CRSP) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

- Industry: Biological Products, (No Diagnostic Substances)
- Last close: $56.56
- Price updated: Sep 21, 2026
- Total congressional trades: 1
- Politicians trading: 1
- Last traded: Feb 24, 2025
- Source: https://tryglasshouse.ai/companies/CRSP.md

## Trading History

- Page: 1 of 1
- Results: 1 of 1
- Pagination query parameter: `page`

## 1. Ashley Moody

- Member: Republican, Senate
- Transaction: Sell, $1,001 - $15,000
- Dates: traded Feb 24, 2025, disclosed Mar 22, 2025
- Market context: $46.57 at trade, $56.56 current (+21.45%)
- Politician: https://tryglasshouse.ai/politicians/M001244.md
- Record: https://tryglasshouse.ai/trades/86d43836-1b5a-4246-aad0-9e745678a39e.md



## About CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Prices and percentage changes are market context, not portfolio returns. This information is not financial advice.